Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 383-385

  Breccia, Massimo ^a   Minotti, Clara ^a   Latagliata, Roberto ^a   Loglisci, Giuseppina ^a   Salaroli, Adriano ^a   Loglisci, Maria Giovanna ^a   Lo Coco, Francesco ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

APL; ATRA; Prognosis

Indexed keywords

IDARUBICIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADULT; AGE; ARTICLE; CANCER CLASSIFICATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; RETINOIC ACID SYNDROME; SEX; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TRETINOIN;

EID: 84875381625     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.014     Document Type: Article

References (11)

1. Grimwade D. The pathogenesis of acute promyelocytic leukemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999, 106:591-613.
2. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-767.
3. Fenaux P., Le Deley M.C., Castaigne S., et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993, 82:3241-3249.
4. Sanz M.A. Treatment of acute promyelocytic leukemia. Hematology 2006, 147-155.
5. Sanz M.A., Lo Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011, 29:495-503.
6. Thepot S., Gardin C., Chevret S., et al. Impact of ATRA duration during the induction treatment of newly diagnosed APL. Blood 2008, 112:139.
7. Mandelli F., Diverio D., Avvisati G., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative groups. Blood 1997, 90:1014-1021.
8. Lo Coco F., Avvisati G., Vignetti M., et al. Front line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010, 116:3171-3179.
9. Lo Coco F., Diverio D., Avvisati G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999, 94:2225-2229.
10. Frankel S.R., Eardley A., Heller G., et al. All trans retinoic acid for acute promyelocytic leukemia: results of the New York Study. Ann Intern Med 1994, 120:278-286.
11. Sanz M.A., Grimwade D., Tallmann M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.